Antinociceptive and anti-inflammatory activities of the ethanol extract from Annona muricata L. leaves were investigated in animal models. The extract delivered per oral route (p.o.) reduced the number of abdominal contortions by 14.42% (at a dose of 200 mg/kg) and 41.41% (400 mg/kg). Doses of 200 and 400 mg/kg (p.o) inhibited both phases of the time paw licking: first phase (23.67% and 45.02%) and the second phase (30.09% and 50.02%), respectively. The extract (p.o.) increased the reaction time on a hot plate at doses of 200 (30.77% and 37.04%) and 400 mg/kg (82.61% and 96.30%) after 60 and 90 minutes of treatment, respectively. The paw edema was reduced by the ethanol extract (p.o.) at doses of 200 (23.16% and 29.33%) and 400 mg/kg (29.50% and 37.33%) after 3 to 4 h of application of carrageenan, respectively. Doses of 200 and 400 mg/kg (p.o.), administered 4 h before the carrageenan injection, reduced the exudate volume (29.25 and 45.74%) and leukocyte migration (18.19 and 27.95%) significantly. These results suggest that A. muricata can be an active source of substances with antinociceptive and anti-inflammatory activities.

The croton oil-induced mouse ear oedema test, acetic acid-induced abdominal writhing, and carrageenan-induced peritonitis were used to study the anti-inflammatory effects of the crude ethanol extract and its alkaloid fraction from Solanum lycocarpum fruits. The alkaloid fraction induced a dose-dependent reduction in ear oedema formation and leukocyte migration, suggesting that S. lycocarpum fruits may contain steroidal alkaloids accounting for the anti-inflammatory effect of the crude ethanol extract.

RESUMOO serviço farmacêutico na Unidade Básica de Saúde (UBS) do Sistema Único de Saúde (SUS) no Brasil garante o acesso a medicamentos de qualidade e contribui para o uso racional para que o paciente seja o principal beneficiário. O objetivo deste estudo foi descrever a importância da assistência farmacêutica (AF) no funcionamento geral das UBSs com um enfoque nos serviços farmacêuticos. Os dados coletados foram organizados a partir de uma revisão da literatura em diferentes fontes bibliográficas. Os achados mostraram que a UBS é a principal porta de entrada para o sistema de saúde e que deve funcionar em conformidade com as normas preconizadas pelo Ministério da Saúde do Brasil. Além disso, é essencial a participação do profissional farmacêutico na gestão clínica dos medicamentos para o desenvolvimento de atividades voltadas aos cuidados farmacêuticos do paciente. Portanto, a AF consiste em um conjunto de ações relacionadas à promoção, proteção e recuperação da saúde, individual e coletiva, tendo o medicamento como insumo essencial e visando ao acesso e uso racional.

Antinociceptive and anti-inflammatory activities of the Muehlenbeckia platyclada leaves’ ethanol extract were investigated in animal models. The extract (p.o.) reduced the number of abdominal contortions induced by acetic acid by 21.57% (400 mg/kg). After intraplantar injection of formalin, a dose of 400 mg/kg (p.o.) inhibited the time spent paw licking in the first phase (26.43%), while the second phase was inhibited by 10.90 and 36.65% at the doses of 200 and 400 mg/kg, respectively. The extract (p.o.) increased the reaction time on a hot plate at a dose of 400 mg/kg (32.68 and 40.30%) after 60 and 90 minutes of treatment, respectively. The paw edema was reduced by extract (p.o.) at doses of 100 (15.46 and 16.67%), 200 (22.68 and 25.64%) and 400 mg/kg (29.50 and 37.33%) after 3 to 4 h of carrageenan application, respectively. Doses of 100, 200 and 400 mg/kg (p.o.), administered 4 h after the carrageenan injection, reduced the exudate volume (11.28, 21.54 and 45.13%), while leukocyte migration was reduced by 21.21 and 29.70% at the doses of 200 and 400 mg/kg, respectively. These results indicate that the ethanol extract from M. platyclada may constitute a potential target for the discovery of new molecules with antinociceptive and anti-inflammatory activities that can be explored for their therapeutic use.

Agonistas do receptor de GLP-1 e inibidores da serino-protease dipeptidil-peptidase-4 no tratamento de diabetes tipo 2-Uma revisão GLP-1 receptor agonists and dipeptidyl-peptidase-4 serine protease inhibitors in the treatment of type 2 diabetes-A review